![]() ![]() If you're in the heart center space, you might recognize a few of the people but I will highlight my favorite quotes here from Dr. And I'm not going to go through all of this. We've talked to a lot of cardiologists and people in this space about the results. But as we realize these initial promising results. This is what I like to call the bit of a bragging slide. So we will able to enable a robust machine learning model in our file and product. And in the beginning of next year, we're starting our larger global generalization study in which we are populating five to 50 patients across a wide range of demography. ![]() This first study the pilot study, and it's closing down on the end of the year. We're also showcasing improved performance in identifying congested patients, as opposed to the standard of care established as of today. And that's comparing to the invasive gold standards. So to give you a bit more background of where we are in the clinical phase, so this is results from our first pilot study, in which we have admitted over 150 patients with these patients who were already demonstrating 95% of our measurement differences falling within the clinically acceptable limits. The richness of data we gather, combined with machine learning models, and the data that we gather in our clinical studies from invasive procedures enable us to present the resulting cardiac insights presented here on the right hand side, namely right atrial pressures, pulmonary artery pressures, as well as pulmonary capillary pressures. So how do we achieve this? Well, we're utilizing what we call the patented save sensor technology system, which is a combination of four sensors, systems, the system, your Cardiography, acoustic PSD, sensors, visual PPG sensor, as well as electric Cardiography. And we believe that this will be able to improve care, improve health outcomes, and save drastic amounts of money for the healthcare systems globally. These measurements reach accuracies equivalent of the invasive gold standards. And it can measure these inter cardio pressures without surgery, just by holding the device against the heart for a few minutes. So it's in the form factor of a smartphone. And this is where we come in, we have to cry, we have developed the world's first non invasive handheld intracardiac blood pressure monitoring device. So as we were looking at this market, we realized that there's a need for a low costs, non invasive and accurate solution for measuring these pressures. What this results in is, of course, high costs, which in the end results in limited applicability and widespread use across healthcare systems. So why are we not doing that at a massive scale? Well, the thing is that all the current intracardiac pressure monitoring solutions in the market are invasive, mainly, they require surgery. You can do this by measuring the intracardiac pressures, what's also committed called the blood pressures within the heart. ![]() So what can you do about this? Well, it's been proven that to improve the discharge decisions, as well as reduce the number of readmissions, with up to as much as 75%. What this of course results in is a massive increase in costs for healthcare system and inefficiencies in the system. And up to 50% of patients are readmitted within six months of leaving the care facilities. What this means is that patients are discharged too early often. And it's diseases, which is very difficult in accurately diagnosing and monitoring, which incurs a lot of issues for the heart, health care professionals. ![]() It's affecting 60 million patients globally. It's a vast global disease area, which costs healthcare systems, over 300 billion US dollars every year. So here's the quick background off the heart failure space. And we are working on what we believe it can become the new standard in heart failure management. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |